Kolltan Pharmaceuticals

Kolltan Pharmaceuticals

Based: New Haven, CT
Raised: $25 million
Investors: HBM Partners AG

The scoop: Kolltan has been developing new oncology therapies based on the scientific work of Yale's Joseph Schlessinger, the co-founder of the company. The biotech has kept a low profile generally, but recently wooed Gerald McMahon, the Senior VP of oncology R&D at MedImmune, into the CEO's job. About 30 staffers are at work at the biotech, which has raised a total of some $75 million. Peter Hirth, the CEO at Plexxikon, sits on the board. The biotech is developing monoclonal antibodies that target receptor tyrosine kinases.

Kolltan Pharmaceuticals
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.